Development of Neutralizing Monoclonal Antibodies for Oncogenic Human Papillomavirus Types 31, 33, 45, 52, and 58

Abstract excerpt

Human papillomavirus (HPV) is the etiological agent for all cervical cancers, a significant number of other anogenital cancers, and a growing number of head and neck cancers. Two licensed vaccines offer protection against the most prevalent oncogenic types, 16 and 18, responsible for approximately 70% of cervical cancer cases worldwide and one of these also offers protection against types 6 and 11, responsible...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cervical Cancer and HPV Research
• Share to Immunotherapy and Immune Responses
• Share to vaccines and immunoinformatics approaches